N1165
吡莫尼唑
≥98% (HPLC), 2-nitroimidazole hypoxia marker, powder
别名:
NSC 380540, PD 126675, Ro 03-8799;, α-[（2-硝基-1H-咪唑-1-基）甲基]-1-哌啶乙醇, α-（（2-硝基咪唑-1-基）甲基）-1-哌啶乙醇;
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C11H18N4O3
CAS Number:
分子量:
254.29
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
生化/生理作用
吡莫尼唑在2位有一个硝基和一个咪唑环。吡莫尼唑经历还原，在缺氧细胞中被激活。
吡莫尼唑是一种高效且无毒的外源性2-硝基咪唑缺氧标志物。
吡莫尼唑是一种高效且无毒的外源性2-硝基咪唑缺氧标志物。吡莫尼唑与蛋白质、肽和氨基酸中的巯基形成加合物。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Yong Chen et al.
Disease models & mechanisms, 12(12) (2019-11-11)
Major risk factors for necrotizing enterocolitis (NEC) are formula feeding and prematurity; however, their pathogenic mechanisms are unknown. Here, we found that insufficient arginine/nitric oxide synthesis limits blood flow in the intestinal microvasculature, leading to hypoxia, mucosal damage and NEC
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Takahiro Minato et al.
Frontiers in physiology, 9, 478-478 (2018-06-06)
Fetal growth restriction (FGR) is a risk factor exacerbating a poor neurological prognosis at birth. A disease exacerbating a poor neurological prognosis is cerebral palsy. One of the cause of this disease is cerebral hemorrhage including intraventricular hemorrhage. It is
Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma
Varia MA, et al.
Gynecologic Oncology, 71(2), 270-277 (1998)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持